I am not sure what he is talking about as it pertains to EDP-235. PFE is using a P-glycoprotein inhibitor to boost intracellular concentration of Paxlovid, not ENTA. Does he or she have data that suggests intracellular EDP-235 is too low to be effective without an such an inhibitor?
If he or she is talking about the EDP-235 phase I safety data making ENTA a buyout target or making ENTA be able to swing a very sweet deal, I am not sure who suggesting or even thinking that. I am not. It will be the phase 2/3 efficacy trial that will do that.